Systemic lupus erythematosus A. clinical and laboratory features

Primer on the Rheumatic Diseases: Thirteenth Edition

Volumn , Issue , 2008, Pages 303-318

  Buyon, Jill P ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892209714     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-68566-3_15     Document Type: Chapter

References (51)

1. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythemato-sus. Arthritis Rheum 1982;25:1271-1277.
2. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40: 1725.
3. Gladman DD. Systemic lupus erythematosus: Clinical features. In: Klippel JH, Weyand CM, Wortmann RL, eds. Primer on the rheumatic diseases. 11th ed. Atlanta: Arthritis Foundation; 1997:267-272.
4. Ginzler EM, Schorn K. Outcome and prognosis in systemic lupus erythematosus. Rheum Dis Clin North Am 1988;14:67-78.
5. Boumpas DR, Fessler BJ, Austin HA, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concepts. Part 2: Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogene-sis. Ann Int Med 1995;123:42-53.
6. Urowitz MB, Bookman AAM, Koehler BE, et al. The bimodal mortality in systemic lupus erythematosus. Am J Med 1976;60:221-225.
7. Urowitz MB, Gladman DD. Accelerated atheroma in lupus-background. Lupus 2000;9:161-165.
8. Mimouni D, Nousari CH. Systemic lupus erythematosus and the skin. In: Lahita R, ed. Systemic lupus erythema-tosus. 4th ed. New York: Elsevier/Academic Press; 2004: 855-876.
9. Hill GS, Delahousse M, Nochy D, et al. A new morphologic index for the evaluation of renal biopsies in lupus nephritis. Kidney Int 2000;58:1160-1173.
10. Appel GB, Silva FG, Pirani CL. Renal involvement in systemic lupus erythematosus (SLE): a study of 56 patients emphasizing histologic classification. Medicine 1978;75: 371-410.
11. Weening, JJ, D'Agati VD, Schwartz MM, et al. Classification of glomerulonephritis in systemic lupus erythemato-sus revisited. J Am Soc Nephrol 2004;15:241-250.
12. Stone JH, Millward CL, Olson JL, Amend WJ, Criswell LA. Frequency of recurrent lupus nephritis among ninety-seven renal transplant patients during the cyclosporine era. Arthritis Rheum 1998;41:678-686.
13. Nossent HC, Swaak TJG, Berden JHM. Systemic lupus erythematosus: analysis of disease activity in 55 patients 1 with end-stage renal failure treated with hemodialysis or continuous ambulatory peritoneal dialysis. Am J Med 1990;89:169-174.
14. Krane NK, Burjak K, Archie M, O'Donovan R. Persistent lupus activity in end-stage renal disease. Am J Kidney Dis 1999;33:872-879.
15. Boumpas DR, Austin HA, Fessler BJ, Balow JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: emerging concepts. Part 1: renal, neuropsychiatric, cardiovascular, pulmonary and hematologic disease. Ann Int Med 1995;122:940-950.
16. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychi-atric lupus syndromes. Arthritis Rheum 2000;42:599-608.
17. West SG, Emlen W, Wener M, Kotzin BL. Neuropsychi-atric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med 1995;99:153-163.
18. Roldan CA, Shively BK, Crawford MH. An echocardio-graphic study of valvular heart disease associated with systemic lupus erythematosus. N Engl J Med 1996;335: 1424-1430.
19. Rosner S, Ginzler EM, Diamond HS, et al. A multicenter study of outcome in systemic lupus erythematosus. II. Causes of death. Arthritis Rheum 1982;25:612-617.
20. Haider YS, Roberts WC. Coronary arterial disease in systemic lupus erythematosus: quantification of degree of narrowing in 22 necropsy patients (21 women) aged 16 to 37 years. Am J Med 1981;70:775-781.
21. Petri M. Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort. Lupus 2000;9:170-175.
22. Manzi S, Selzer F, Sutton-Tyrrell K, et al. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999;42:51-60.
23. Roman MJ, Shanker BA, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349:2399-2406.
24. Asanuma Y, Chung CP, Oeser A, et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 2006;33:539-545.
25. Winslow TM, Ossipov MA, Fazio GP, Simonson JS, Redberg RF, Schiller NB. Five-year follow-up study of the prevalence and progression of pulmonary hypertension in systemic lupus erythematosus. Am Heart J 1995; 129:510-515.
26. DeGiorgio LA, Konstantinov KN, Lee SC, Hardin JA, Volpe BT, Diamond B. A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus. Nature Med 2001;7:1189-1193.
27. Schur PH, Sandson J. Immunologic factors and clinical activity in systemic lupus erythematosus. N Engl J Med 1968;278:533-538.
28. Bootsma H, Spronk P, Derksen R, et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995; 345:1595-1599.
29. Tseng CE, Buyon JP, Kim M, et al. The effect of moderate-dose corticosteroids in preventing severe flares in patients with serologically active, but clinically stable, systemic lupus erythematosus: findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:3623-3632.
30. Amoura Z, Koutouzov S, Chabre H, et al. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases. Antinucleosome antibodies of the IgG3 subclass are marker of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum 2000;43: 76-84.
31. Rovin BH, Song H, Hebert LA, et al. Plasma, urine, and renal expression of adiponectin in human systemic lupus erythematosus. Kidney Int 2005;68:1825-1833.
32. Li Y, Tucci M, Narain S, et al. Urinary biomarkers in lupus nephritis. Autoimmun Rev 2006;5:383-438.
33. Sesin CA, Yin X, Esmon CT, Buyon JP, Clancy RM. Shedding of endothelial protein C receptor contributes to vasculopathy and renal injury in lupus: in vivo and in vitro evidence. Kidney Int 2005;68:110-120.
34. Rivera TL, Izmirly PM, Buyon JP, Clancy RM. Contribution of vasculopathy to lupus nephritis: endothelial protein C receptor levels and genotype [abstract]. Arthritis Rheum 2006;54:S824-S825.
35. Petri M, Howard D, Repke J. Frequency of lupus flares in pregnancy. The Hopkins Lupus Pregnancy Center experience. Arthritis Rheum 1991;34:1538-1545.
36. Urowitz MB, Gladman DD, Farewell VT, Stewart J, McDonald J. Lupus and pregnancy studies. Arthritis Rheum 1993;36:1392-1397.
37. Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005;52:514-521.
38. Buyon J, Kalunian K, Ramsey-Goldman R, et al. Assessing disease activity in SLE patients during pregnancy. Lupus 1999;8:677-684.
39. Lockshin MD, Reinitz E, Druzin ML, Murrman M, Estes D. Lupus pregnancy. Case control prospective study demonstrating absence of lupus exacerbation during or after pregnancy. Am J Med 1984;77:893-898.
40. Lockshin MD. Pregnancy does not cause systemic lupus erythematosus to worsen. Arthritis Rheum 1989;32:665-670.
41. Buyon JP, Tamerius J, Ordorica S, Abramson SB. Activation of the alternative complement pathway accompanies disease flares in systemic lupus erythematosus during pregnancy. Arthritis Rheum 1992;35:55-61.
42. Tandon A, Ibanez D, Gladman DD, Urowitz MB. The effect of pregnancy on lupus nephritis. Arthritis Rheum 2004;50:3941-3946.
43. Buyon JP, Hiebert R, Copel J, et al. Autoimmune-associated congenital heart block: Mortality, morbidity, and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998;31:1658-1666.
44. Buyon JP, Winchester RJ, Slade SG, et al. Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children: comparison of ELISA and immunoblot to measure anti-SSA/Ro and anti-SSB/La antibodies. Arthritis Rheum 1993;36:1263-1273.
45. Buyon JP, Clancy RM. Neonatal lupus. In: Wallace DJ, Hahn, BH, eds. Dubois' lupus erythematosus. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2006:1058-1080.
46. Derksen RH, Khamashta MA, Branch DW. Management of the obstetric antiphospholipid syndrome. Arthritis Rheum 2004;50:1028-1039.
47. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295-306.
48. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990;87:4120-4124.
49. Mongey A-B, Hess EV. Drug and environmental systemic lupus erythematosus: clinical manifestations and differences. In: Lahita R, ed. Systemic lupus erythematosus. 4th ed. New York: Elsevier/Academic Press; 2004:1211-1240.
50. Lahita R, ed. Systemic lupus erythematosus. 4th ed. New York: Elsevier/Academic Press; 2004.
51. Wallace DJ, Hahn BH, eds. Dubois' lupus erythematosus. 7th ed. Philsdelphia: Lippincott Williams & Wilkins; 2006.